Squamous Cell Carcinoma News and Research RSS Feed - Squamous Cell Carcinoma News and Research

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.
MGH study may lead to first nonsurgical treatment for seborrheic keratoses

MGH study may lead to first nonsurgical treatment for seborrheic keratoses

An investigation into the molecular mechanisms responsible for the most common type of benign skin lesion may lead to the first nonsurgical treatment for the growths called seborrheic keratoses (SKs), which in addition to being cosmetically unattractive are often worrisome to patients. [More]
New NCCN Guidelines published for Vulvar Cancer

New NCCN Guidelines published for Vulvar Cancer

It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the disease[i]. In order to provide comprehensive, up-to-date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer Network, an alliance of 26 of the nation's leading cancer centers, has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer. [More]
Immunotherapy could be the future of cancer treatments

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
Discovery could pave way for targeted therapies to treat penile cancer

Discovery could pave way for targeted therapies to treat penile cancer

Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments. [More]
OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016. [More]
OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.5 million of securities in a registered direct offering. [More]
New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. These results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic. This work is being presented Oct. 28 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29. [More]
OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July 31, 2015. [More]
UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern Medical Center surgeons are helping to pioneer a trend that extends the advantages and benefits of minimally invasive surgery to patients who need middle ear surgery. [More]
Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers. [More]
UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the deadliest form of brain cancer. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma. [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Researchers identify genetic abnormalities that lead to skin SCC

Researchers identify genetic abnormalities that lead to skin SCC

Squamous cell carcinoma (SCC) of the skin is one of the most frequent cancers in humans affecting more than half million new persons every year in the world. The transformation of a normal cell to a cancer cell is caused by an accumulation of genetic abnormalities in the progeny of single cells. The spectrum of genetic anomalies found in a variety of human cancers have been described. [More]
New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New research from the Johns Hopkins Bloomberg School of Public Health suggests that the protein keratin 17 - the presence of which is used in the lab to detect and stage various types of cancers - is not just a biomarker for the disease, but may play a critical role in tumor growth. [More]
Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim today announced The Lancet Oncology has published results from the LUX-Lung 8 trial. LUX-Lung 8 is the largest, prospective Phase III head-to-head trial directly comparing two EGFR-directed treatments. [More]

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active. [More]
Advertisement
Advertisement